Rhenman & Partners Asset Management AB acquired a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $1,798,000. A number of other hedge […]